Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death worldwide. So far, almost all treatments are almost ineffective for pancreatic cancer. Thus, there is an urgent need to develop novel therapeutics for pancreatic cancer treatment. Immune checkpoints blockade therapies, including anti-PD-L1 and anti-PD-1, show promising anti-tumor efficacy for a various type of solid tumors. However, pancreatic cancer is disappointed for anti-PD-L1 therapy alone. The expression level of PD-L1 is considered as one of determinant of checkpoint immunotherapy efficacy. The far upstream element-binding protein 1 (FUBP1) is an important transactivator of c-Myc proto-oncogene. Here, we demonstrate that FUBP1 is overexpressed in pancreatic cancer and associated with poor prognosis. Moreover, we show that FUBP1 promotes tumor cell proliferation and migration and regulates the cancer cell immunity by increasing the PD-L1 expression mediated by Myc in pancreatic cancer cells. Taken together, these findings uncover important aspects of the function of FUBP1 in cancer immunity and elucidated the specific mechanism regulating PD-L1 expression. Targeting FUBP1 may be a novel therapeutic strategy to overcome the immunotherapy resistance in pancreatic cancer. (C) 2018 Elsevier Inc. All rights reserved.